Cor Vasa 2010, 52(7-8):393-396 | DOI: 10.33678/cor.2010.106

The diagnosis and treatment of the most common form of restrictive cardiomyopathy: cardiac amyloidosis

Kateřina Linhartová
Kardiologické oddělení, Kardiovaskulární centrum, Fakultní nemocnice Motol, Praha, Česká republika

The most common restrictive cardiomyopathy is light-chain (AL) amyloidosis with an estimated prevalence of 8-10/1 mil. pop. The clinical picture is a combination of non-specific general symptoms with presentations of heart failure. The principal diagnostic method is echocardiography showing myocardial wall thickening and increased stiffness leading to left ventricular diastolic dysfunction. The gold standard is histologic evidence of amyloid with its immunohistochemical or immuno-electron microscope typing. Treatment is performed in close collaboration with a department of hematology, or even there, and is designed to inhibit the formation of amyloidogenic protein. If initiated early, treatment of AL amyloidosis may improve the hitherto very grim prognosis of these patients.

Keywords: Restrictive cardiomyopathy; AL amyloidosis; Echocardiography; Diastolic dysfunction

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Linhartová K. The diagnosis and treatment of the most common form of restrictive cardiomyopathy: cardiac amyloidosis. Cor Vasa. 2010;52(7-8):393-396. doi: 10.33678/cor.2010.106.
Download citation

References

  1. Elliott P, Anderson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008;29: 270-276. Go to original source... Go to PubMed...
  2. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart. Arch Intern Med 2006:166:1805-1813. Go to original source... Go to PubMed...
  3. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected amyloidosis. Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51:1022-1030. Go to original source... Go to PubMed...
  4. Falk RH. Diagnosis and management of cardiac amyloidoses. Circulation 2005;112:2047-2060 Go to original source... Go to PubMed...
  5. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of AL amyloidosis Br J Haematol 2008;140:365-377. Go to original source... Go to PubMed...
  6. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371. Go to original source... Go to PubMed...
  7. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light-chain (AL) amyloidosis. Arch Intern Med 2005;165:1425-1429. Go to original source... Go to PubMed...
  8. Ariarajah V, Steiner I, Hájková P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009;113:132-137. Go to original source... Go to PubMed...
  9. Baethge BA, Jacobson DR. Amyloidosis, overview. eMedicine 2009. http://www.emedicine.com/med/topic3377.htm.




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.